Completed PHASE3 INTERVENTIONAL 2-arm NCT01385371

A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma (Protocol No. P08067)

Sponsor: ALK-Abelló A/S

Conditions Conjunctivitis Rhinitis Allergic

Interventions Grass (Phleum pratense) pollen allergen extract Placebo for SCH 697243

Updated 7 times since 2017 Last updated: Jan 18, 2017 Started: Jun 30, 2011 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Conjunctivitis and Rhinitis Allergic, this trial is completed. The trial is conducted by ALK-Abelló A/S and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
May 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ALK-Abelló A/S

Data source: ALK-Abelló A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.